Recent news about King Charles’ prostate issues and subsequent cancer diagnosis has raised awareness of such health issues nationwide. Although the king is not diagnosed with prostate cancer, his efforts to raise awareness among older men have been widely appreciated.
The charity Prostate UK is using billboards to encourage men across the country to assess their cancer risk and consult their GP if they experience symptoms like frequent or difficult urination. However, prostate cancer is a complex and subtle condition.
The prostate, located below the bladder, tends to enlarge with age. The urethra, the tube draining urine from the bladder to the outside, passes through it. When the prostate enlarges, it can put pressure on the urethra, causing symptoms like dribbling and increased frequency of urination. This condition is quite common.
Similarly, prostate cancer is also common. Autopsy studies show that 36% of whites and 51% of African Americans develop prostate cancer in their 70s. There are even cases of prostate cancer found in 5% of men under 30 in autopsy studies. However, not all forms of prostate cancer are equally dangerous, with some being harmless and others potentially fatal.
How dangerous is prostate cancer?
Prostate cancer accounts for around 4% of male deaths in the UK, with approximately 12,000 people dying from it each year. The challenge lies in finding treatments that do not cause further harm, as treatments like surgery and radiation therapy can lead to side effects such as erectile dysfunction and incontinence.
The lack of an accurate way to differentiate between aggressive and non-aggressive tumors is a major problem. The PSA test, developed in the 90s, was introduced to monitor men’s response to prostate cancer treatment. However, the increasing number of diagnoses did not correspond to a reduction in mortality rates.
In the US, the Preventive Services Task Force has offered recommendations for or against PSA screening. While screening may slightly reduce prostate cancer deaths, it can also lead to unnecessary testing and treatments for non-fatal conditions.
To avoid unnecessary treatment, the “watchful waiting” approach has been effective in managing localized prostate cancer with low mortality rates. In the UK, the National Screening Committee does not recommend PSA screening for prostate cancer.
Research suggests that identifying harmful cancers through prostate screening MRI scans may be a viable solution, although more evidence is needed to assess its impact on reducing deaths without overtreatment.
Read more:
Source: www.sciencefocus.com
